But that was published 2017 and was for Airsonea (previous name)? I thought they only received the CE and TGA for Wheezo last year and there was no mention of what CE Mark it was, hence I asked the question here. Also it looks like the clinical data used to support the approval was tested against the stethoscope which was mentioned in 2019 AGM presentation and that they were going to conduct clinical trial against the clinician standard of spirometry, etc, due for completion this year. But they said they applied for FDA approval last year, do you know if the clinical trial data used to support this approval was also against the stethoscope and if the trial was conducted in the US?
https://*********.com.au/respiri-wheezo-product-approved-sale-ce-mark-tga-registration/
https://hotcopper.com.au/threads/an...ration.4683333/?post_id=37847475#.XrYigmgzZPY
Respiri investor Presentation, page-39
-
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RSH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.0¢ |
Change
-0.002(4.76%) |
Mkt cap ! $51.39M | |||
| Open | High | Low | Value | Volume |
| 4.2¢ | 4.3¢ | 3.7¢ | $301.9K | 7.521M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 369145 | 4.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.1¢ | 131324 | 1 |
View Market Depth
| Last trade - 15.45pm 04/10/2024 (20 minute delay) ? |
| RSH (ASX) Chart |